Amanda L Robichaud Selected Research

Ewing Sarcoma (Sarcoma, Ewing)

1/2021	STAG2 loss rewires oncogenic and developmental programs to promote metastasis in Ewing sarcoma.
1/2019	A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.
1/2018	Genome-scale CRISPR-Cas9 screen identifies druggable dependencies in TP53 wild-type Ewing sarcoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Amanda L Robichaud Research Topics

Disease

7	Neoplasms (Cancer) 01/2022 - 01/2018
3	Leukemia 11/2023 - 01/2021
3	Neuroblastoma 01/2022 - 12/2018
3	Ewing Sarcoma (Sarcoma, Ewing) 01/2021 - 01/2018
2	Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (T-ALL) 11/2023 - 01/2022
1	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 01/2022

Drug/Important Bio-Agent (IBA)

2	Proteins (Proteins, Gene)FDA Link 11/2023 - 01/2021
2	EnzymesIBA 01/2022 - 01/2022
2	ChromatinIBA 01/2021 - 12/2018
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 11/2023
1	avapritinibIBA 11/2023
1	Phosphotransferases (Kinase)IBA 11/2023
1	AntibodiesIBA 01/2022
1	CarbonIBA 01/2022
1	Folic Acid (Vitamin M)FDA LinkGeneric 01/2022
1	Methotrexate (Mexate)FDA LinkGeneric 01/2022
1	pyrimidineIBA 01/2022
1	Serine (L-Serine)FDA Link 01/2022
1	purineIBA 01/2022
1	Adrenergic Agents (Adrenergic Drugs)IBA 01/2022
1	Hydroxymethyl and Formyl TransferasesIBA 01/2022
1	CohesinsIBA 01/2021
1	Drug CombinationsIBA 01/2019
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 01/2019
1	P5091IBA 01/2018
1	Peptides (Polypeptides)IBA 01/2018
1	ATSP-7041IBA 01/2018
1	GSK2830371IBA 01/2018
1	Proto-Oncogene Proteins c-etsIBA 01/2018
1	Oncogene Proteins (Oncogene Protein)IBA 01/2018

Therapy/Procedure

7	Therapeutics 11/2023 - 01/2018
1	Immunotherapy 01/2022